CORDIS
EU research results

CORDIS

English EN
Personalised Postoperative Immunotherapy To Improving Cancer Outcome and improving quality of life

Personalised Postoperative Immunotherapy To Improving Cancer Outcome and improving quality of life

Objective

During this RISE project we aim to develop nanoparticle-based encapsulated libraries of different immunotherapeutic
biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the
management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective
treatment option for many types of cancer today and it is considered curative treatment for most solid tumours. It forms part
of a multidisciplinary approach used in conjunction with radiotherapy or chemotherapy. These approaches, however, have
several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with
chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can
relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state. Our
proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions.
This includes a) new methods to identify immune gene profiles and biomarkers b) transgenic mouse models where the
complex interactions that underlie immune function can be visualised as multiplexed events in real time and c) the use of
nanoparticle-based libraries of immune modulating reagent combinations. There are three key objectives within this project:
i) to use immune gene signatures to monitor disease progression and therapeutic efficacy of immunotherapy combinations
on nanoparticle-based platforms, ii) to optimise the platform to encapsulate libraries of immune components for more
personalised, accurate and timely delivery of the payload to its intended target and iii) to optimise the overall cancer
management process of image-guided surgery followed by postoperative immunotherapy so that we can ultimately provide a
lifetime of protection against cancer.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

PERCUROS BV

Address

Plesmanlaan 1
2333 Bz Leiden

Netherlands

Activity type

Other

EU Contribution

€ 324 000

Participants (17)

Sort alphabetically

Sort by EU Contribution

Expand all

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 162 000

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 108 000

TECHNISCHE UNIVERSITEIT DELFT

Netherlands

EU Contribution

€ 108 000

UNIVERSITA DEGLI STUDI DI CAMERINO

Italy

EU Contribution

€ 108 000

TECOBIOSCIENCES GMBH

Germany

EU Contribution

€ 108 000

UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 108 000

THE UNIVERSITY OF SHEFFIELD

United Kingdom

EU Contribution

€ 108 000

UNIVERSITEIT MAASTRICHT

Netherlands

EU Contribution

€ 108 000

JENACELL GMBH

Germany

EU Contribution

€ 108 000

MEDRES-MEDICAL RESEARCH GMBH

Germany

EU Contribution

€ 108 000

AUGEAS ASSOCIAZIONE DI SPORT PROMOZIONE E TURISMO

Italy

EU Contribution

€ 108 000

PROGREDUM GMBH

Germany

EU Contribution

€ 108 000

ASSOCIAZIONE CULTURALE CASTELLI ROMANI GREEN TOUR

Italy

EU Contribution

€ 108 000

BOSCHIVA MELCHIORRI SRL

Italy

EU Contribution

€ 216 000

HELRIK AND LOUW COMPANY LTD

United Kingdom

EU Contribution

€ 162 000

UNIWERSYTET JAGIELLONSKI

Poland

EU Contribution

€ 108 000

ASSOCIAZIONE HAND IN HAND

Italy

EU Contribution

€ 162 000

Project information

Grant agreement ID: 777682

Status

Ongoing project

  • Start date

    1 March 2018

  • End date

    28 February 2022

Funded under:

H2020-EU.1.3.3.

  • Overall budget:

    € 2 430 000

  • EU contribution

    € 2 430 000

Coordinated by:

PERCUROS BV

Netherlands